INDEX
EASL ANNUAL REPORT 2012

2 INTRODUCTION

3 EASL GOVERNING BOARD

4 EASL MISSION

5 EASL’S ANNUAL MEETING: THE INTERNATIONAL LIVER CONGRESS™

10 YEARLY CALENDAR OF EDUCATIONAL ACTIVITIES
  • EASL SPECIAL CONFERENCE
  • EASL MONOTHEMATIC CONFERENCE

13 EASL SCHOOLS OF HEPATOLOGY

14 EASL MEMBERSHIP

15 EASL SHEILA SHERLOCK FELLOWSHIP PROGRAMME
  • SHORT-TERM TRAINING
  • ENTRY-LEVEL RESEARCH
  • POST-DOC RESEARCH
  • PHYSICIAN SCIENTIST PROGRAMME

16 EASL MENTORSHIP NEW

17 CONCERTED ACTION GROUPS

19 EASL E-LEARNING

20 EASL CLINICAL PRACTICE GUIDELINES

21 EASL EU AND PUBLIC AFFAIRS PROGRAMME

23 THE JOURNAL OF HEPATOLOGY

24 FINANCIAL REPORT 2012

25 THE EASL BUILDING

27 AUDITOR’S REPORT OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
INTRODUCTION

These are very exciting times for the field of Hepatology and the European Association for the Study of the Liver in particular. EASL was founded almost 50 years ago as a society to promote and exchange science in the field of liver diseases. Until today this remains the most important task to EASL. We are happy to witness the exciting data presented at the International Liver Congress™ (ILC) and to be published in our Journal, the Journal of Hepatology, which can today be regarded as one of the two premier Journals in the field of liver disease.

In 2012, the International Liver Congress™ in Barcelona turned out to be a record breaking success. With over 9,400 participants, EASL reached an all-time high which was way beyond all expectations. The attendance in the various sessions was tremendous and the feedback on the quality of the sessions received from the attendees was very positive. Another highlight of ILC 2012 was the successful launch of the smart phone and tablet application iLiver which enables medical expert’s quick reference to regularly updated information on liver diseases and treatment.

Apart from the International Liver Congress™, there have been other successful educational events over the last year including the joint EASL-AASLD Special Conference dedicated to Therapy of Hepatitis C: Clinical application and drug development in Prague, the Monothematic Conference on HIV in London, which was co-sponsored and supported by the European Aids Clinical Society (EACS), and the different Schools of Hepatology, which reached record breaking attendance again this year.

Also in 2012, EASL continued promoting research not only through presentations at events but also through an ever increasing number of fellowships to young investigators including the Sheila Sherlock Fellowships, the Short Term Fellowships, and the Physician Scientist Fellowship, which allows clinicians to take some time off clinical duties and devote to research. In addition, in times of increasing competition for young doctors in many fields of medicine, EASL is dedicated to help attract the brightest brains into the field of Hepatology and therefore launched the Mentorship programme in November this year. EASL tries to provide our young and talented colleagues with the skills and the contacts they need to succeed in the highly competitive field of liver disease research.

EASL is also recognising that with shrinking resources and an ageing population in Europe, public health issues are becoming increasingly important. This is why EASL is now undertaking considerable efforts to work with the commission and the European Parliament not only for putting more emphasis on liver disease research but also for putting more attention to the rather neglected field of chronic liver disease.

Thank you for continued commitment to EASL and support in our efforts in the global fights against liver disease.

Prof. Markus Peck-Radosavljevic, MD

Dr. Laurent Castera

EASL SECRETARY GENERAL

EASL VICE-SECRETARY
EASL GOVERNING BOARD

EASL is an association dedicated to the pursuit of excellence in liver research and in the clinical practice of liver disorders. EASL is run by a Governing Board of 11 experts (the Secretary General, Vice-Secretary, Treasurer, 5 Scientific Committee members, the EU Policy Councillor and 2 Educational Councillors) actively engaged and involved in the discipline. Our aim is to actively involve young scientists and hepatologists in a wide range of educational activities to stimulate their contribution and support their research. Throughout its history, EASL has endeavoured to raise awareness and stimulate interest in liver disease. In doing so, EASL has attracted an ever growing number of experts and sponsors concerned with the health and wellbeing of individuals all over the world. We invite all those who wish to take up the challenge, to join EASL and to become part of our vision.

Secretary General
Mark Thursz, London, UK

Vice-Secretary
Markus Peck, Vienna, Austria

Treasurer
Mauro Bernardi, Bologna, Italy

Scientific Committee member
Matías A. Avila, Pamplona, Spain

Scientific Committee member
Frank Lammert, Homburg, Germany

Scientific Committee member
George V. Papatheodoridis, Athens, Greece

Scientific Committee member
Daniele Prati, Lecco, Italy

Scientific Committee member
Tania Roskams, Leuven, Belgium
(replaced by Laurent Castera, Clichy, France in April 2012)

EU Policy Councillor
Dominique-Charles Valla, Clichy, France
(replaced by Patrizia Burra, Padua, Italy in April 2012)

Educational Councillor
Jean-François Dufour, Bern, Switzerland

Educational Councillor
Fabien Zoulim, Lyon, France
EASL MISSION

EASL provides professional leadership in the liver disease arena and aims to:

- **REDUCE THE PREVALENCE OF LIVER DISEASE IN OUR COMMUNITY AND WORLDWIDE**
- **MINIMIZE THE SUFFERING OF PATIENTS AND TO PREVENT LIVER RELATED DEATHS**
- **PROMOTE CLINICAL, BASIC AND TRANSLATIONAL RESEARCH**
- **FOSTER INTERNATIONAL SCIENTIFIC EXCHANGE**
- **ADVISE EUROPEAN HEALTH AUTHORITIES CONCERNING LIVER DISEASES, THE PROVISION OF CLINICAL SERVICES, AND THE NEED FOR RESEARCH FUNDING**
- **RAISE PUBLIC AWARENESS OF LIVER DISEASES AND THEIR MANAGEMENT**
The International Liver Congress™ is the annual meeting of the European Association for the Study of the Liver (EASL). It is held every year in April in major European cities with adequate facilities and easy travel connections from all continents. The congress has a scientific programme composed of State-of-the-Art lectures and a large number of symposia complemented by oral and poster presentations for which abstracts are submitted. The congress begins with Joint Workshops followed by a Postgraduate Course providing an overview of different features in Hepatology. The programme content is developed as State-of-the-Art presentations with a special emphasis on clinical practice, as well as question and answer sessions to foster interaction with the audience and to evaluate the overall benefit of the course. The educational value of the course is also evaluated by questionnaires completed by the audience. Past EASL Postgraduate Courses include:

- MANAGEMENT OF ACUTE CRITICAL CONDITIONS IN HEPATOLOGY - Vienna 2010
- CHOLESTATIC DISEASES OF THE LIVER AND BILE DUCTS – Berlin 2011
- ALCOHOLIC LIVER DISEASE – Barcelona 2012

9,415 participants attended the International Liver Congress™ 2012
April 18-22, Barcelona - Spain
The International Liver Congress™ 2012 held in Barcelona, Spain, April 18 - 22 was again a tremendous success. This was EASL’s 47th annual meeting and attendance had never been so high with 9,415 registered delegates. A new initiative was launched with the organisation of a Nurses and Associates Forum. This Forum with leading nurse-physician faculty provided plenary presentations and case discussions on managing collaboratively, complex patient populations. The response to this exciting opportunity to share practice from an international perspective was overwhelming and therefore continues to be included again in the scientific programme for the International Liver Congress™ 2013 in Amsterdam.

Furthermore, the 2012 meeting introduced a joint EASL-IASL (International Association for the Study of the Liver) Postgraduate Course. The topic for this year’s Course was Alcoholic Liver Disease, the importance of which is indisputable given that it remains the most common cause of cirrhosis and liver mortality in Europe. All aspects of alcoholic liver disease from public health to transplantation were covered in order to provide a comprehensive educational opportunity.

The International Liver Congress™ 2012 also hosted 14 national liver associations located in the National Associations Village onsite in Barcelona in the aim to showcase liver-related actions and activities at local level. A record number of 141 journalists attended and the global media reach generated from the 1,338 articles written was estimated at 175,816,308 persons.

In order to reach out to a wider community, EASL used its Facebook page www.easl.eu/facebook and its Twitter account dedicated solely to the International Liver Congress™ www.twitter.com/ILCpress.

Networking and exchange of knowledge were optimised with cutting edge applications such as Q4U and Chance2Meet. Q4U, a sophisticated and focused Q&A session, was implemented during the Postgraduate Course. This system enabled delegates to text questions to speakers in real time, while lectures were being given and allowed participants to accurately test their knowledge. Finally, EASL breached the record of 3,633 members from all over the world thanks to those who renewed membership or joined the EASL community on site.

The International Liver Congress™ 2013 (EASL’s 48th annual congress) to be held in April 2013 in Amsterdam, The Netherlands is set to be an equally record breaking event with an expected turnout of over 9,500 registered delegates. A full account of this meeting will be provided in the 2013 Annual Report.
# FACTS AND FIGURES

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Congress</th>
<th>Venue</th>
<th>Number of Registered Delegates</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>48</td>
<td>Amsterdam</td>
<td>over 9,500 expected!</td>
</tr>
<tr>
<td>2012</td>
<td>47</td>
<td>Barcelona</td>
<td>9,415</td>
</tr>
<tr>
<td>2011</td>
<td>46</td>
<td>Berlin</td>
<td>8,062</td>
</tr>
<tr>
<td>2010</td>
<td>45</td>
<td>Vienna</td>
<td>7,602</td>
</tr>
<tr>
<td>2009</td>
<td>44</td>
<td>Copenhagen</td>
<td>7,017</td>
</tr>
<tr>
<td>2008</td>
<td>43</td>
<td>Milan</td>
<td>7,480</td>
</tr>
<tr>
<td>2007</td>
<td>42</td>
<td>Barcelona</td>
<td>5,769</td>
</tr>
<tr>
<td>2006</td>
<td>41</td>
<td>Vienna</td>
<td>5,162</td>
</tr>
</tbody>
</table>

**BARCELONA 2012 CONGRESS STATISTICS**

Top 10 participating countries / Number of delegates

<table>
<thead>
<tr>
<th>Rank</th>
<th>Country</th>
<th>Delegates</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>USA</td>
<td>1131</td>
</tr>
<tr>
<td>2</td>
<td>Germany</td>
<td>653</td>
</tr>
<tr>
<td>3</td>
<td>Italy</td>
<td>647</td>
</tr>
<tr>
<td>4</td>
<td>Spain</td>
<td>635</td>
</tr>
<tr>
<td>5</td>
<td>France</td>
<td>624</td>
</tr>
<tr>
<td>6</td>
<td>UK</td>
<td>546</td>
</tr>
<tr>
<td>7</td>
<td>China</td>
<td>381</td>
</tr>
<tr>
<td>8</td>
<td>Switzerland</td>
<td>254</td>
</tr>
<tr>
<td>9</td>
<td>Brazil</td>
<td>228</td>
</tr>
<tr>
<td>10</td>
<td>Russia</td>
<td>216</td>
</tr>
</tbody>
</table>
THE INTERNATIONAL LIVER CONGRESS™ 2012
PARTICIPANTS BY WORLD REGIONS

WESTERN EUROPE 50%

EAST ASIA & PACIFIC 11.40%

NORTH AMERICA 13.40%

EASTERN EUROPE 9.20%

MIDDLE EAST 7.20%

CENTRAL & SOUTH AMERICA 5.60%

AFRICA & ATLANTIC 2.80%

CENTRAL ASIA 1.20%

THE INTERNATIONAL LIVER CONGRESS™ 2012 BY EASL AUDIENCE BREAKDOWN

INDIVIDUAL PARTICIPANTS 4141

PHARMA INDIVIDUAL 2776

COMPLIMENTARY/ACCOMPANYING 1838

PHARMA GROUPS 662
THE INTERNATIONAL LIVER CONGRESS™ 2012
PARTICIPANTS BY WORK PLACE

- UNIVERSITY: 7%
- HOSPITAL: 22%
- INDUSTRY: 19%
- UNIVERSITY HOSPITAL: 35%
- PRESS: 2%
- LABORATORY: 2%
- RESEARCH INSTITUTE: 6%
- PRIVATE PRACTICE: 5%
- AUTRE: 3%
- PRIVATE: 5%
- UNIVERSITY: 7%
- RESEARCH INSTITUTE: 6%
- PRIVATE PRACTICE: 5%
- AUTRE: 3%
- PRIVATE: 5%
- UNIVERSITY: 7%
- RESEARCH INSTITUTE: 6%
- PRIVATE PRACTICE: 5%
- AUTRE: 3%
- PRIVATE: 5%

THE INTERNATIONAL LIVER CONGRESS™ 2012 BY EASL
PARTICIPANTS BY PROFESSIONAL EXPERTISE

- HEPATOLOGY: 57.6%
- INFECTIOUS DISEASES: 14.1%
- GASTROENTEROLOGY: 13.8%
- MICROBIOLOGY/VIROLOGY: 5.1%
- INTERNAL MEDICINE: 3%
- PHARMACOLOGY: 2.4%
- CELL BIOLOGY: 2.4%
- PATHOLOGY: 1.5%
- TRANSPLANT SURGERY: 1.2%
- RADIOLOGY/IMAGING: 0.6%
Beyond its annual meeting, EASL also organises a wide range of activities and key educational events in the field of hepatology. Once a year, EASL hosts a Special Conference attracting between 500 and 800 participants. The scientific programme of each Special Conference is built around a single topic discussed in a State-of-the Art format.

In 2012, EASL joined efforts with the American Association for the Study of Liver Disease (AASLD) to produce a Special Conference dedicated to Therapy of Hepatitis C: Clinical application and drug development. This Special Conference was held in Prague, Czech Republic on September 14-16. Major discussion points of the conference included:

- How to use the new DAAs in real-world settings
- How to manage side-effects
- Efficacy in populations not treated in pivotal registration trials

Such information is vital for physicians starting to use these drugs in order to know which patients should be treated now. Another exciting element is perspectives on IFN-free treatment regimens. After more than 25 years, therapies can no longer be developed that will not require interferon alpha which is known to cause many side-effects and is also very expensive. Hepatologists today are clearly experiencing a paradigm shift in the therapy of hepatitis C and the 2012 EASL-AASLD Special Conference can be considered as a milestone meeting for the development of new guidelines in Europe.

One Special Conference is programmed for 2013.

- Liver Cancer Management,
  June 20-23, 2013, Istanbul, Turkey
Following the conference on IMLI that took place in Hamburg in 2008, the EASL Governing Board decided to repeat this successful event in 2012.

Immune-mediated liver injury is the common pathway that underpins most of the liver diseases treated in Europe, including viral hepatitis, toxic liver damage, autoimmune liver disease and steatohepatitis. Understanding the mechanisms involved would allow us to develop much needed treatments for chronic liver disease.

Central issues addressed included:
- Innate Immunity and Liver Disease
- The Gut–Liver Axis an Important Driver of Inflammatory Liver Disease
- Tolerance and Immune Regulation
- Immune Mediated Liver Injury

The Vascular Liver Diseases conference in Tallinn, Estonia addressed a spectrum of conditions including hepatitis, cirrhosis, steatohepatitis, cancer and more. Understanding the mechanisms involved would allow us to develop much needed treatments for chronic liver disease.

EASL believed this was an opportune time to review exciting recent developments in the field and to this end an outstanding programme with leading international authorities in the field was assembled. An important element of the meeting was discussions and interactions between delegates and speakers which led to collaborations and the dissemination of ideas and knowledge.
Lexicon: State-of-the-art applies to the highest level of development in a scientific field achieved at a particular time, as a result of modern methods. The State-of-the-art format referred to above makes reference to the most recent and best, up-to-the-minute scientific data.
The EASL Schools of Hepatology have continued to evolve since they started in 2003. These educational events are held apart from the International Liver Congress™ and aim to diffuse the highest standards in basic and clinical hepatology. The schools are intended as a series of events covering different aspects in the field of liver disease.

The EASL Schools of Hepatology target young fellows enrolled in hepatology-oriented departments, or more experienced clinicians who want to be exposed to the newest trends in hepatology. Participants have to apply for a place on the course; application for the EASL Schools of Hepatology is free and open to young fellows under the age of 35 and/or still in training.

For selected applicants, EASL will cover transportation costs to attend the school and accommodation during the event. Approximately 30 places are available for each school and priority is given to registered EASL members during the selection process.

Courses are usually held in a medical institute, research centre or university. The school format is that of a residential course with a limited attendance. The schools offer intense interaction, plenty of time for personal discussions and exchange with a distinguished faculty as well as a balanced blend of lectures on theoretical and practical issues with clinical case-based discussions.

The EASL Educational Councillors and Governing Board review programmes proposed by the chairs. The Educational Councillors review all the applications from young hepatologists and select the candidates primarily based on their dedication to hepatology and their age. Priority is given to first time participants and to select a small number of participants (30 to 40 maximum) in order to facilitate discussions during each course.

Each year, EASL organises 1 Basic School of Hepatology and 2 Clinical Schools of Hepatology. In 2012, EASL organised the following schools:

- **EASL BASIC SCHOOL OF HEPATOLOGY COURSE 7:**
  HEPATOCYTE DAMAGE & LIVER METABOLISM,
  FEBRUARY 29-MARCH 1, 2012, TRIESTE, ITALY

- **EASL CLINICAL SCHOOL OF HEPATOLOGY COURSE 18:**
  LIVER IMAGING,
  JUNE 7-9, 2012, BOLOGNA, ITALY

- **EASL CLINICAL SCHOOL OF HEPATOLOGY, COURSE 19:**
  LIVER TRANSPLANTATION AND ACUTE LIVER FAILURE,
  DECEMBER 14-15, 2012, LONDON, UNITED KINGDOM
MEMBERSHIP

EASL is a renowned society of clinicians and scientists striving to promote liver research and improve the treatment of liver diseases worldwide. EASL gathers members from all over the world and has over 3000 members.

THERE ARE 5 MEMBERSHIP CATEGORIES:

- **REGULAR**
  (for individuals from Europe and Israel)
- **CORRESPONDING**
  (for individuals from non-European countries)
- **EMERITUS**
  (for regular members over 65 years that have been EASL members for at least 10 years)
- **TRAINEE**
  (for trainees up to 35 years. Proof of age and trainee status is required)
- **CORPORATE**
  (Special conditions for EASL sponsors – please see the EASL Sponsorship brochure for conditions)

MEMBERSHIP BENEFITS INCLUDE:

- **Free annual subscription** to the Journal of Hepatology
- **Reduced registration fees** to the International Liver Congress™ and to all other EASL Meetings
  (see [www.easl.eu](http://www.easl.eu) for full details)
- **Free and instant access** to over 500 multimedia presentations from congresses and e-Series available in both webcast and iPhone/iPad compatible video podcasts
- Possibility to host fellows as part of the EASL Fellowship Programme
- Possibility to organise EASL Monothematic and Special Conferences
- Possibility to host one of the EASL Schools of Hepatology
- EASL bi-monthly ‘What’s New?’ newsletters and quarterly ‘EU Bulletin’
- **Financial support** for the application
  to the EU Research Framework Programme (FP7)

FUTURE MEMBERSHIP INITIATIVE:

**EASL GREEN MEMBERSHIP**

EASL is planning to update its membership structure as from 2013 in an effort to become a greener and eco-friendly association. A “Green Package” will be introduced:

EASL members will have access to an online version of the Journal of Hepatology and EASL membership will no longer include the printed version of the journal. This initiative is designed to both develop environmental awareness for EASL members and promote green alternatives for printed content. A full account of EASL’s Green Membership will be provided in the 2013 Annual report.
EASL SHEILA SHERLOCK FELLOWSHIP PROGRAMME

EASL launched its first research fellowship programme in 1997 to enhance the mobility of investigators within different European institutions, to encourage continued learning and research, and to actively promote scientific exchange among research units in hepatology. The fellowships were dedicated to the memory of Prof. Dame Sheila Sherlock, hence the name EASL Sheila Sherlock Fellowship Programme.

The fellowships have been a great success and EASL currently supports up to 20 laureates each year investing around 500,000€ in post-doctorat, entry-level and short-term training. Due to the ever increasing number of requests from researchers, EASL launched an additional fellowship opportunity in 2011. The new physician-scientists fellowship programme enables practicing physician-scientists to take leave from their clinical duties for 6-12 months in order to pursue research in a research laboratory.

The following fellowship programmes are available:

- POST-DOCTORATE (UP TO 3 FELLOWSHIPS EACH YEAR)
- ENTRY-LEVEL (UP TO 3 FELLOWSHIPS EACH YEAR)
- PHYSICIAN-SCIENTISTS (1 SIX MONTH FELLOWSHIP AND 1 TWELVE MONTH FELLOWSHIP EACH YEAR)
- SHORT-TERM (MAXIMUM OF 3 MONTHS)

→ Full details of the fellowships programmes can be found on www.easl.eu/_fellowship
As of November 2012, EASL offered 2 Mentorship programmes per year. The Mentorship programme has been created as a means of enhancing scientific exchange and personal developmental relationships in which a more experienced and knowledgeable hepatologist will guide a young investigator (registered EASL members under the age of 35 and/or still in training) through a crucial stage of their career path.

The Mentorship programme is a 12 months programme and entails informal face-to-face communication during a sustained period of time, between the mentor (who is perceived to have greater relevant knowledge in the field of hepatology) and the mentee (who is perceived to have less experience). The programme is not simply about answering ad hoc questions or providing occasional help, it is about establishing an ongoing relationship (continuous learning, dialogue, and challenge).

Mentoring is a process that involves communication and is relationship based, it is a process enabling the informal transmission of knowledge and a means of support for the mentee that is relevant to work, career, and professional development.

2 prominent EASL members have volunteered and been deemed as mentors by the EASL Governing Board for 2012/2013:

- **Prof. Jaime Bosch**, Barcelona, Spain (Expert in Portal Hypertension)
- **Prof. Massimo Colombo**, Milan, Italy (Expert in HCC)

The Mentorship programme will be reviewed mid 2013 during an EASL Governing Board meeting to determine the success and future of the programme. A full account of this programme will be summarised in the 2013 Annual report.

Further details of the Mentorship programme can be found on [www.easl.eu/_fellowship/mentorship](http://www.easl.eu/_fellowship/mentorship)
CONCERTED ACTION GROUPS

BASIC SCIENCE CONCERTED ACTION GROUP (BS-CAG)

The Basic Science Concerted Action Group (BS-CAG) is an advisory group to EASL’s Governing Board. It is formed by basic scientists working in various fields and disciplines that are of interest for Hepatology research.

THE AIMS OF THE BS-CAG:

• Provide advice to the EASL GB on “hot” new developments/topics in basic science, helping to design relevant content for various events like the Basic Science Seminar during the International Liver Congress™ (ILC), Basic Science Schools and Monothematic conferences
• Review the programmes for the Basic Science Seminar, Schools of Hepatology, and Monothematics Conferences
• Promote the interaction between clinical researchers and basic scientists with common interests in all the different aspects of liver biology and disease
• Make the latest technological developments in molecular analysis accessible to clinical researchers
• Foster the interaction between clinical researchers and basic scientists. The benefits of mutual interaction include the exchange of human samples, technology, experimental models, and know-how

BS-CAG PROPOSALS AND INITIATIVES

In 2012, the following future events were proposed by the BS-CAG:

• Basic School of Hepatology: Course Epithelial Mesenchymal Interactions in Liver Development, Diseases and Cancer. January 24-25, 2014, Milan, Italy
• Monothematic Conference: Microbiota, Metabolism and Non-Alcoholic Fatty Liver Disease. February 26-28, 2015, Innsbruck, Austria
• Monothematic Conference: Management of Metabolic Disorders on Liver Disease. 2016, Sevilla, Spain

INTERNATIONAL LIVER CONGRESS™ 2013

• Basic State of the Art Lecture: Endoplasmic Reticulum Stress Signaling, Inflammation, and Liver Metabolism
• Basic Science Seminar: Immunology and the Liver
• Basic Grand Round: Investigational Approaches in the Gut Microbiota
• Translational Workshop: Modulation of Liver Injury and Metabolism through Bile Acids Receptors

PUBLIC HEALTH CONCERTED ACTION GROUP (PH-CAG)

The Concerted Action Group in Public Health (PH-CAG) was created to improve and strengthen EASL’s approach to public health issues. The group focuses on different aspects of Public Health, i.e. health burden, social impacts, prevention, control, screening strategies for several forms of liver diseases and their consequences.
THE AIMS OF THE PH-CAG:

- Attract scientists and healthcare providers with interest in public health, prevention and control of liver disease
- Improve the role of EASL in providing educational activities in these fields
- Assist the EASL Governing Board on public health issues, and on the organisation of initiatives in this field
- Review EASL Clinical Practice Guidelines and other official documents related to public health issues
- Facilitate the relationship with existing public health boards, and improve lobbying and cooperation initiatives with official institutions

PH-CAG PROPOSALS AND INITIATIVES

In 2012, the following initiatives were proposed by the PH-CAG:

- Contribute to the International Liver Congress™ 2013 programme
- Provide review and comments on the Literature Review (scheduled to be launched early 2013)
- Provide initial input for the 2013 event programme

YOUNG INVESTIGATORS CONCERTED ACTION GROUP (YI-CAG)

EASL strives to provide Young Investigators with the best opportunities for development in the field of Hepatology. Throughout the years, EASL has developed several fellowships and bursary programmes to enable young scientists to participate in its congresses and meetings.

In an effort to evaluate the needs of young scientists, the EASL Governing Board has decided to create a Young Investigators Concerted Action Group (YI-CAG). The reason of being of this group is to work on the diverse programmes offered to Young Investigators during the International Congress™ (YI Forum and Seminar).

In July 2011, 103 Young Investigators voted for their new representative and Dr. Vincenzo Cardinale was elected. His appointment will enable him to represent all young hepatologists currently still in training, and to voice opinions, needs and proposals. The top five Young Investigators where then invited to create the first YI-CAG.

The YI-CAG meets twice a year, once during the International Liver Congress™ and once before EASL's September Governing Board meeting.

THE AIMS OF THE YI-CAG:

- Build an active and dynamic community of Young Investigators
- Promote and facilitate discussion and exchange of information
- Host an exclusive social event during the International Liver Congress™ solely for Young Investigators

YI-CAG PROPOSALS AND INITIATIVES

In 2012, the following initiatives were proposed by the YI-CAG:

- Young Investigators dedicated web platform: Young Investigators Social Network
  Designed to collect and condense all Young Investigators related programmes and initiatives under one dedicated platform. Here Young Investigators can share experiences and communicate directly with each other and EASL as an association.

- The Young Investigators Lounge during the International Liver Congress™
  In an effort to enable networking between Young Investigators the YI-CAG had suggested for the ILC 2013 the creation of the YI-Lounge dedicated to Young Investigators only. Here Young Investigators will be allowed to relax and share insights with other fellow investigators all in an effort to build a strong sense of community for the group.

- EASL Masterclass
  This new addition to EASL's event calendar will focus on scientific and professional coaching sessions for Young Investigators. The course will include a balanced mix of scientific and professional workshops. The EASL Masterclass is a unique occasion to enhance professional and personal skills by learning from the best EASL experts in Hepatology.
EASL E-LEARNING

EASL has continuously developed a wide range of e-learning tools with specialised educational content allowing those interested in hepatology to expand their knowledge on liver disease whilst learning through virtual meetings from across the globe. EASL members can download selected courses, listen to original and exclusive talks, take part in interactive quizzes, view and create multimedia presentations from an e-library of webcasted conferences.

EASL e-learning tools include: webcasts and video podcasts of Monothematic Conferences, Special Conferences, State-of-the-Art lectures and Post-Graduate Courses from the International Liver Congress™, in addition to selected symposia from conferences dedicated specifically to hepatology. EASL also provides online presentations available free to its members in the form of e-series where special topics are covered in depth by experts in the field, and e-posters enabling users to search for specific content, as well as make comments on posters and ask questions to authors.

To centralize the majority of these e-learning tools, EASL has been developing an e-learning portal called LiverTree™ in 2012. LiverTree™ will be a one stop educational website for EASL members, featuring the most advanced search tool in the field of liver research and assessed by liver experts.

This new educational platform will centralize and organize thousands of EASL educational materials published over the past eight years all in one location. It will offer a wide range of educational content, including webcasts of selected EASL courses and conferences, accredited courses, e-series, case studies, learning quizzes, video podcasts, documents, congress materials and much more. It will also include e-learning components such as accredited courses (UEMS) and genuine breakthrough concepts in online education that will change the way hepatologists query and retrieve accurate information within EASL lectures. EASL members will be exposed to a patent pending concept that provides them with the ability to instantly find and retrieve 100% accurate and precise portions of lectures without the need for first time users to enter any keyword.

LiverTree™ is planned to be officially launched during the International Liver Congress™ 2013 in Amsterdam, The Netherlands.

In a continuous effort to provide innovative educational tools, EASL has developed the iLiver app throughout 2011. This electronic text book of medicine for iPhone and iPad enables medical experts quick reference to regularly updated information on liver diseases and treatment. The iLiver app will provide easy-to-access EASL validated and frequently updated medical information related to liver diseases in an interactive format that can be used at the bedside by physicians worldwide. The iLiver app was officially launched at the International Liver Congress™ in Barcelona 2012. After its launch, the app has been downloaded 8,300 times throughout 2012. An Android version of the application is currently under development and will be launched early 2013. Additional upgrades regarding the translation of the application to several other languages and the addition of two new chapters ‘Pediatrics’ and ‘Alpha 1 Antitrypsin Deficiency’ are also scheduled for 2013.
EASL CLINICAL PRACTICE GUIDELINES

EASL has developed a range of Clinical Practice Guidelines (CPGs) since the first issue that was released in October 2008. These guidelines are distributed via the Journal of Hepatology and define the use of diagnostic, therapeutic and preventive modalities, including non-invasive and invasive procedures, in the management of patients with various liver diseases. They are intended to assist physicians and other healthcare providers as well as patients and interested individuals in the clinical decision making process by describing a range of generally accepted approaches for the diagnosis, treatment and prevention of specific liver diseases.

EASL has already produced the following Clinical Practice Guidelines:

- MANAGEMENT OF CHRONIC HEPATITIS B
- MANAGEMENT OF CHOLESTATIC LIVER DISEASES
- MANAGEMENT OF HFE HEMOCHROMATOSIS
- MANAGEMENT OF ASCITES, SPONTANEOUS BACTERIAL PERITONITIS, AND HEPATORENAL SYNDROME IN CIRRHOSIS

In 2011, CPGs on the Management of Hepatitis C Virus Infection were released. The following four publications for 2012:

- MANAGEMENT OF WILSONS DISEASE
- MANAGEMENT OF HEPATOCELLULAR CARCINOMA
- REVISED CLINICAL PRACTICE GUIDELINES ON THE MANAGEMENT OF CHRONIC HEPATITIS B
- MANAGEMENT OF ALCOHOLIC LIVER DISEASE

AASLD/EASL joint guidelines on Hepatic Encephalopathy

In autumn 2009, initial discussions began between AASLD and EASL regarding the creation of joint AASLD/EASL Practice Guidelines. A letter of agreement was signed in September 2010 and work began on the development of guidelines on Hepatic Encephalopathy. These guidelines, approved by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, shall represent the position of both associations from a European and American perspective. The document is intended for use by physicians, and the recommendations shall suggest preferred approaches to the diagnostic, therapeutic and preventive aspects of care. The AASLD/EASL Practice Guidelines are intended to be flexible, in contrast to standards of care, which are often inflexible policies to be followed in every case. Specific recommendations are to be based on relevant published information. The writing group has continued their efforts throughout 2011 and a first formal draft review was planned for summer 2012 followed by a second revision by October 2012. The manuscript is planned to be finalised and sent to the AASLD and EASL Governing Boards for approval and co-publication in Hepatology and the Journal of Hepatology in early 2013.
EASL EU & PUBLIC AFFAIRS PROGRAMME

AIMS AND OBJECTIVES

EASL continues to focus on five main areas of work whilst promoting research in Hepatology and increasing public awareness of liver disease. Our work since 2008 has given us substantial returns and we continue to be recognised as THE voice of the liver community in Brussels. This recognition helps us raise the profile of liver disease among all stakeholders, including the different EU institutions (Parliament, Commission and Council). By positioning ourselves as one of the main healthcare professional groups actively working in Brussels we have ensured that our voice is heard and that more funding is allocated to liver disease research.

Our overall objectives for the coming months include ensuring liver disease research funds are available through Horizon 2020 and other European Commission funding instruments. EASL also works with other stakeholders to promote the development of policies aimed at preventing liver disease and as part of this work we will continue to work with key MEPs with a view to forming an interest group.

RESOURCES

The EASL Governing Board remains committed to the EU Public Affairs programme and throughout 2012 Prof. Markus Peck-Radosavljevic, EASL Vice-Secretary and Prof. Patrizia Burra, EASL’s new EU Policy Councillor headed the EASL EU Public Affairs team, working closely with one staff member based at the EASL Office.

ALCOHOL HEALTH POLICY

EASL continues to be an active member of the European Alcohol and Health Forum (EAHF), the European Commission’s platform where members active at European level can debate, compare approaches and act to tackle alcohol related harm. EASL’s membership of EAHF allows for increased interaction with the Directorate General for Health and Consumers (DG SANCO) and also for collaboration with various NGOs and the establishment of contacts with umbrella organisations in alcohol-related industry and trade.

As part of its on-going commitment to the EAHF, EASL organised a Monothematic Conference on Alcoholic Liver Disease in December 2010. In 2011 and 2012, EASL’s commitment was the publication and distribution of the EASL Clinical Practice Guidelines on the Management of Alcoholic Liver Disease.

Throughout 2012 EASL continued to consolidate relationships with new stakeholders, including working with Eurocare, Alcohol Concern, EMNA, EUFAMI, ELPA and Lundbeck. A report of the different roundtable meetings held will be published in early 2013. In addition, plans are underway to work together on the organisation of the first European Awareness Week on Alcohol Related Harm.

Finally, EASL followed closely, and strongly supported the initiative of the Scottish Government to introduce a minimum unit price for alcohol. In its efforts to engage policy makers in the debate EASL visited a member of Vice-President Tajani’s office in Brussels and followed up by providing information regarding the benefits and the importance of the MUP implementation.
VIRAL HEPATITIS

EASL, working with other stakeholders in the field of viral hepatitis, identifies the key issues in the management of infection and making proposals to the relevant policymakers to help address issues related to education and management of viral hepatitis.

EASL continues to work closely with the European Liver Patients Association (ELPA) and the World Hepatitis Alliance (WHA) in an effort to ensure that the burden of viral hepatitis does not grow. As a result EASL has been involved, and participated in, a number of events held at the European Parliament. In addition, EASL, ELPA and WHA have worked together to try to ensure that Viral Hepatitis is properly included in the European Cancer Code which is currently being updated.

On the occasion of World Hepatitis Day 2012 EASL called on the United Nations to join the effort to tackle viral hepatitis. This is a particularly important topic as the Millennium Development Goals (MDGs) are currently undergoing a review, with the current goals coming to an end in 2015. It is EASL's view that the impact of the exclusive emphasis on HIV, TB and malaria in policies continues to compromise any achievements made in sustainable development.

Over the coming year our focus will continue to be on working towards achieving a council recommendation/ conclusion on viral hepatitis screening that acknowledges the high burden the disease places on health systems and puts in place measures to identify the large number of undiagnosed carriers.

LIVER CANCER

Over the last months EASL has focused firmly on establishing closer links with other stakeholders in the field of cancer. As a result, EASL has been invited to participate in events which have been held at the European Parliament, mainly related to highlighting the links between viral hepatitis/alcohol and liver cancer. In addition, we continue to work with the European Partnership Against Cancer, an initiative launched by DG SANCO, and have taken part in meetings which have led to the publication of a consensus paper regarding quality criteria for health checks.

RESEARCH

Working to fulfil its mission of promoting research in Hepatology, EASL has engaged in direct contact with officials at the Directorate-General for Research and Innovation (DG RESEARCH) with a view to ensuring that liver disease features in Calls published under the 7th Framework Programme. In addition, over the last year EASL has been involved in providing input to the Commission and Parliament with a view to helping structure the funding strategy which will be implemented from 2014 to 2020: Horizon 2020.

EASL’s provision of input to the Commission and Parliament has been both direct and through our membership of the Alliance for Biomedical Research (Biomed Alliance). EASL joined the Alliance in 2010 aware that policymakers often fail to see the link between a strong and competitive research sector and a healthy and active population. As part of the Biomed Alliance, and working together with other organisations, EASL is looking to underline this win-win situation to those in Member States who make the decisions on research priorities and budgets. EASL member Prof. Michael Manns continues to be the joint EASL/UEG representative to the Biomed Alliance working group which has been looking into the basis for the call for a European Health Council for Research (EuHCR).

Finally, as in previous years, EASL has continued to support the work of its members through its FP7 support programme. For the 2012 Calls EASL provided grants to four different projects, one of which was successful at stage II. The PathCo (Pathogen Co-infection: HIV-1, Tuberculosis, Malaria and hepatitis C virus) project consortium is at present in negotiations with the Commission regarding the final amount it will receive for the project.

CHRONIC DISEASES

Since 2010 EASL has been a member of the European Chronic Disease Alliance (ECDA), a consortium of professional and patient groups that work together to ensure public health policies are in place which address the major determinants of ill-health in Europe i.e. alcohol, tobacco, obesity and lack of physical exercise. Throughout 2012 ECDA continued to work to provide DG SANCO with input to its EU Reflection Process on Chronic Disease. The full document, which was submitted to DG SANCO, continued to be disseminated to interested stakeholders throughout 2012.
THE JOURNAL OF HEPATOLOGY

The Journal of Hepatology is the official Journal of the European Association for the Study of the Liver (EASL), the leading liver association in Europe. Since its founding in 1985, the journal has seen an impressive development and readership numbers are ever increasing. The yearly EASL membership fee includes an annual subscription to the Journal of Hepatology.

Throughout 2012, the editorial office have continued to make huge efforts to improve the lay out of the Journal, to better control the quality of the papers published and have strived to bring the most updated state-of-the-art content. In this year, the Journal of Hepatology obtained an impact factor of 9.858. With this impact factor, the official journal of EASL is ranked number 5 in the ISI category: «Gastroenterology and Hepatology» (source: Thomson® Scientific) which is a continued testament to the journal’s outstanding relevance in the field.

The Editorial Team 2011-2012 includes one Editor-In-Chief, two Co-Editors, eighteen Associate Editors, nine Special Section Editors, two Focus Editors, two Web Editors and a Statistical Consultant. A new development for the Journal is the establishment of a Central Editorial Office located within the EASL headquarters in Geneva, Switzerland, which is comprised of one Editorial Manager, one Editorial Assistant, one Medical Illustrator, and one freelance Graphic Designer. All manuscript submissions are managed through the new Elsevier Editorial System.

Some of the previously published sections continue in the new version of the Journal but under new names and several new sections have appeared. The Journal has introduced a Focus section to highlight the most poignant manuscripts in each issue. While Hepatology Snapshot briefly aims to describe either a basic mechanism of a molecular pathway, a detailed application of a new drug, or a schematic representation of a clinical aspect in hepatology. The Clinical Application of Basic Science section provides the reader with further insights into basic science within and outside the field of hepatology which have potential clinical application for hepatologists. The section Frontiers in Liver Transplantation provides insight into the most recent breakthroughs in the transplantation field and emphasizes that it is now considered a permanent trend within the field of hepatology. Highly debated issues are highlighted in Controversies in Hepatology. This section summarizes the pros and cons of specific issues on a current clinical and basic subject. The most relevant papers published in other journals are highlighted in the International Hepatology section. The section Letters to the Editor provides short comments on topical issues or readers’ reactions to articles published in the Journal.

The Journal has developed a new website, with new features including Issue Highlights, Editor’s Picks, a selection of the most interesting reviews and Special Sections, and videocasts commenting on relevant papers published in the Journal. The material is updated twice a month for each published issue.

This year the Journal has implemented the graphical abstract feature: a single, concise, pictorial and visual summary of the main findings of the article, which captures the content at a single glance. Moreover, a new design for the Snapshot section has been developed. To adapt to the evolving global communication, users can now find the Journal of Hepatology on Facebook, Twitter, LinkedIn and Google+.

An iPad edition of the Journal is currently under development and will be launched in 2013.
The 2012 income, as shown in the figure below, exceeded that of the provisional budget presented at the EASL Business Meeting held during the International Liver Congress™ in Barcelona, April 2012. This was mainly due to a further increase in membership and the huge success of the International Liver Congress™ that was attended by over 9,000 delegates. Once again, thanks go to the Banque Cantonale Vaudoise, EASL’s banking partner, as income from investments exceeded expected figures, despite the persisting unfavourable financial context due to the worldwide economic crisis.

The main sources of income for 2012 were represented by the International Liver Congress™ revenues (≈ 48%) and the unrestricted support from Premium Sponsors (≈ 21%): Bristol-Myers Squibb, Gilead, M.S.D., and Roche. EASL memberships accounted for ≈ 9.5%.

Thanks to the outstanding success of the 2012 International Liver Congress™, revenues from the event had enabled EASL to reach 45% of its global income.

The provisional income for 2013 is expected to be close to €4.5 million. The 2013 International Liver Congress™ in Amsterdam is expected to be another great success and will most probably provide revenue enabling the association to once more cover over 40% of the global income. The support from Premium Sponsors has also been secured for 2013.
In an effort to optimize the association’s investment strategy, EASL’s banking partner has recommended a 7% Cash; 88% Bonds; and 5% Stocks investment mix. At the end of 2011 EASL’s investment mix was at 30% Cash; 60% Bonds; and 2% Stocks, clearly un-optimised with a surplus in un-used cash.

To accommodate the offices growth and to balance out EASL’s investment mix. The EASL Governing Board has approved a real estate investment project resulting in a purchase of a building to act as the official EASL headquarters.

EASL’s new headquarters provides both space for the associations expansion, and an additional source of revenue from additional office space to be rented out. The expected return on investment from the purchase of the building is 4% to 7% compared to AAA bonds which are at a maximum of 3.8%

As a result from the real estate investment, EASL’s 2012 investment mix is now closer to the recommended levels with 11% in Cash, 87% in Bonds, and 3% in Stocks.

As in 2011, 2012 expenses almost matched what was anticipated in the provisional budget, as shown in the figure above. There were some unforeseen operational expenses, such as losses from exchange rates and bank fees, accounting and contract consultations, and from real estate related costs due to the acquisition of the new EASL Building.

The expenses for EASL events were within budget; the fellowship budget allocated was not entirely used as EASL received fewer renewal requests than expected. There were also fewer expenses regarding i-Tools, as not all of them were fully developed during 2012. To promote the association, the EASL booth was present at a higher number of meetings, and this required more funding than expected.

The expenses related to the Journal of Hepatology were within budget. To this respect, the Editorial team of the Journal has to be praised for their efforts in reducing costs. Lastly, there were greater costs for the EASL Office, related to the recruitment of two new employees.
The increase in expenses foreseen in 2013 is mainly due to:

- Fellowships - in order to pay overhead expenses to the hosting institutions,
- Launch of the Mentorship programme,
- EASL Masterclass – EASL will introduce a new type of school, focusing on a mix of scientific and professional topics designed around the needs of young investigators,
- i-Tools - to support several projects such as new chapters and translations for the iLiver application, EASL websites, and the development of the LiverTreeTM,
- EU policy activities - to foster initiatives such as the EASL Literature Review White Paper on the Burden of Liver Disease in Europe and Hepamap, as well as financial support for a greater number of applications to EU,
- Promotion of the association by participating in various congresses worldwide with the EASL booth,
- New Data Collection project,
- Additional building expenses.

As a final point, the EASL Office will increase the number of projects that will be directly managed in-house, and this will require the recruitment of additional employees.

As a result, the provisional balance for the 2013 budget is expected to be €204,912.

To conclude, the commitment of EASL in providing its members with services is witnessed by the fact that almost 2/3 of the expenses are devoted to this purpose, as illustrated in the final figure.

### EXPENSES 2012 SERVICES TO MEMBERS

<table>
<thead>
<tr>
<th>PERCENTAGE OF TOTAL EXPENSES</th>
<th>0%</th>
<th>5%</th>
<th>10%</th>
<th>15%</th>
<th>20%</th>
<th>25%</th>
</tr>
</thead>
<tbody>
<tr>
<td>J HEPATOLOGY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FELLOWSHIPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEETINGS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU POLICY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTHERS*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Others include: clinical practice guidelines, webcasting, website, and tools

### Balance sheet as of 31st December

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>3'874</td>
<td>4'208</td>
</tr>
<tr>
<td>Working accounts banks</td>
<td>3'750'933</td>
<td>6'405'071</td>
</tr>
<tr>
<td>Investment deposit</td>
<td>7'640'825</td>
<td>7'673'207</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>841'127</td>
<td>247'978</td>
</tr>
<tr>
<td>Withholding tax</td>
<td>1'925</td>
<td>6'777</td>
</tr>
<tr>
<td>VAT receivable</td>
<td>10'315</td>
<td>38'305</td>
</tr>
<tr>
<td>Accrued assets</td>
<td>13'955</td>
<td>0</td>
</tr>
<tr>
<td>Computer</td>
<td>10'122</td>
<td>0</td>
</tr>
<tr>
<td>Building</td>
<td>5'332'288</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>17'605'366</td>
<td>14'375'546</td>
</tr>
<tr>
<td><strong>LIABILITIES AND SHAREHOLDERS’ EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortgage</td>
<td>1'887'380</td>
<td>0</td>
</tr>
<tr>
<td>Accrued liabilities Expenses</td>
<td>764'380</td>
<td>552'819</td>
</tr>
<tr>
<td>Accrued liabilities Membership</td>
<td>298'966</td>
<td>274'811</td>
</tr>
<tr>
<td>Accrued liabilities Journal</td>
<td>165'000</td>
<td>165'000</td>
</tr>
<tr>
<td>Accrued liabilities Sponsors</td>
<td>406'800</td>
<td>552'482</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>3'552'526</td>
<td>1'545'111</td>
</tr>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital contribution</td>
<td>1'842'618</td>
<td>1'842'618</td>
</tr>
<tr>
<td>Result brought forward</td>
<td>10'987'817</td>
<td>9'875'847</td>
</tr>
<tr>
<td>Result for the period</td>
<td>1'222'405</td>
<td>1'111'970</td>
</tr>
<tr>
<td><strong>Total equity</strong></td>
<td>14'052'840</td>
<td>12'830'435</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND EQUITY</strong></td>
<td>17'605'366</td>
<td>14'375'546</td>
</tr>
</tbody>
</table>
### Profit and Loss account for the period from 1st January to 31st December

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EUR</td>
<td>EUR</td>
</tr>
<tr>
<td><strong>REVENUES FROM THE ASSOCIATION’S ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership fees</td>
<td>468'110</td>
<td>417'758</td>
</tr>
<tr>
<td>Revenue from annual congress (ILC)</td>
<td>2'467'800</td>
<td>1'988'957</td>
</tr>
<tr>
<td>UEGW</td>
<td>57'143</td>
<td>57'143</td>
</tr>
<tr>
<td>Royalties from the Journal of Hepatology</td>
<td>181'672</td>
<td>180'000</td>
</tr>
<tr>
<td>Support from industry</td>
<td>1'022'482</td>
<td>1'000'000</td>
</tr>
<tr>
<td>Other income</td>
<td>74'365</td>
<td>70'054</td>
</tr>
<tr>
<td><strong>Total revenues from the association’s activities</strong></td>
<td><strong>4'271'572</strong></td>
<td><strong>3'713'912</strong></td>
</tr>
<tr>
<td><strong>FINANCIAL REVENUES AND COSTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gain on investment</td>
<td>1'240</td>
<td>0</td>
</tr>
<tr>
<td>Loss on investment</td>
<td>-6'422</td>
<td>-9'248</td>
</tr>
<tr>
<td>Unrealised investment gain</td>
<td>565'708</td>
<td>118'357</td>
</tr>
<tr>
<td>Unrealised investment loss</td>
<td>-19'916</td>
<td>-107'314</td>
</tr>
<tr>
<td>Financial income</td>
<td>279'532</td>
<td>332'193</td>
</tr>
<tr>
<td>Financial charges</td>
<td>-27'164</td>
<td>-19'917</td>
</tr>
<tr>
<td>Exchange loss</td>
<td>-58'106</td>
<td>-75'447</td>
</tr>
<tr>
<td>Exchange gain</td>
<td>91</td>
<td>44'639</td>
</tr>
<tr>
<td><strong>Net Financial income</strong></td>
<td><strong>734'963</strong></td>
<td><strong>283'264</strong></td>
</tr>
<tr>
<td><strong>Total income</strong></td>
<td>5'006'535</td>
<td>3'997'175</td>
</tr>
</tbody>
</table>

### EXPENSES

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>EASL congress &amp; conferences (Monothematic + Special Conf)</td>
<td>635'311</td>
<td>333'514</td>
</tr>
<tr>
<td>Schools of Hepatology</td>
<td>96'923</td>
<td>112'516</td>
</tr>
<tr>
<td>GB honorarium &amp; GB secretariat</td>
<td>125'000</td>
<td>125'100</td>
</tr>
<tr>
<td>GB meetings</td>
<td>107'404</td>
<td>114'805</td>
</tr>
<tr>
<td>Investment meetings</td>
<td>0</td>
<td>902</td>
</tr>
<tr>
<td>BMI Meetings</td>
<td>0</td>
<td>4'267</td>
</tr>
<tr>
<td>Professional consultants (lawyers, accountant, audit,...)</td>
<td>115'637</td>
<td>93'478</td>
</tr>
<tr>
<td>Sister societies meetings &amp; promotion</td>
<td>109'555</td>
<td>55'441</td>
</tr>
<tr>
<td>Endorsed meetings</td>
<td>30'022</td>
<td>40'021</td>
</tr>
<tr>
<td>Concerted Action Groups</td>
<td>3'813</td>
<td>10'539</td>
</tr>
<tr>
<td>International activities</td>
<td>0</td>
<td>1'179</td>
</tr>
<tr>
<td>Real estate investigations</td>
<td>2'954</td>
<td>8'160</td>
</tr>
<tr>
<td>Press agency</td>
<td>87'443</td>
<td>56'499</td>
</tr>
<tr>
<td>Clinical Practice Guidelines</td>
<td>4'568</td>
<td>10'158</td>
</tr>
<tr>
<td>EU policy activities / EU Public affairs</td>
<td>267'902</td>
<td>199'814</td>
</tr>
<tr>
<td>Fellowships</td>
<td>481'694</td>
<td>466'000</td>
</tr>
<tr>
<td>Communication &amp; E-tools</td>
<td>236'301</td>
<td>246'947</td>
</tr>
<tr>
<td>Journal of Hepatology</td>
<td>231'515</td>
<td>200'871</td>
</tr>
<tr>
<td>EASL Office – General Administration</td>
<td>1'195'223</td>
<td>810'064</td>
</tr>
<tr>
<td>VAT</td>
<td>52'862</td>
<td>-5'070</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>3'784'130</strong></td>
<td><strong>2'885'206</strong></td>
</tr>
<tr>
<td><strong>Results for the period</strong></td>
<td><strong>1'222'405</strong></td>
<td><strong>1'111'970</strong></td>
</tr>
</tbody>
</table>
Companies are invited to support EASL’s aims and educational activities on an annual basis through Premium Sponsorship. EASL wishes to take this opportunity to thank its Premium Sponsors for their commitment and unrestricted educational grants supporting a vast educational programme throughout 2012 as described in this Annual Report.

**PREMIUM SPONSORSHIP**

EASL \[European Association for the Study of the Liver\] PREMIUM SPONSOR

**WHY WE SUPPORT EASL...**

**Bristol-Myers Squibb**
A global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines. We are committed to Helping Advance the Management of Liver Disease.

**Gilead**
Gilead Sciences discovers and develops innovative medicines in areas of unmet need. Aiming to improve patient care in life-threatening diseases, our commitment includes over a decade of liver disease research.

**Roche**
Life writes the questions - We pursue the answers. When it comes to disease there are as many questions as people. We can’t provide an answer to them all. But we can help with our expertise. That’s why Roche supports EASL.

**MSD**
From developing new therapies that treat and prevent disease to helping people in need, we’re committed to improving health and well-being around the world. This is why we support EASL in promoting state-of-the-art education to physicians and scientists.